ストックスクリーナーアプリを入手
13.10
0.61%
0.08
前日終値:
$13.02
開ける：
$12.97
24時間の取引高:
989.23K
Relative Volume:
0.79
時価総額：
$662.16M
収益：
-
当期純損益:
$-156.39M
株価収益率:
-3.5501
EPS:
-3.69
ネットキャッシュフロー:
$-123.06M
1週間 パフォーマンス:
-3.82%
1か月 パフォーマンス:
+14.61%
6か月 パフォーマンス:
+10.36%
1年 パフォーマンス:
+40.48%
1日の値動き範囲:
$12.82
$13.67
1週間の範囲:
$12.82
$14.97
52週間の値動き範囲:
$7.30
$17.28
Kalvista Pharmaceuticals Inc Stock (KALV) Company Profile
名前
Kalvista Pharmaceuticals Inc
セクター
電話
(857) 999-0075
住所
200 CROSSING BOULEVARD, FRAMINGHAM, MA
KALV を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
KALV
Kalvista Pharmaceuticals Inc
|
13.10 | 658.11M | 0 | -156.39M | -123.06M | -3.69 |
|
VRTX
Vertex Pharmaceuticals Inc
|
426.76 | 107.15B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
755.90 | 77.46B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
436.38 | 58.90B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
918.92 | 56.55B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
198.76 | 42.58B | 447.02M | -1.18B | -906.14M | -6.1812 |
Kalvista Pharmaceuticals Inc Stock (KALV) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-01-31 | 開始されました | JMP Securities | Mkt Outperform |
| 2025-01-07 | 開始されました | TD Cowen | Buy |
| 2024-12-18 | 開始されました | BofA Securities | Buy |
| 2020-06-15 | 開始されました | H.C. Wainwright | Buy |
| 2019-07-29 | 開始されました | SVB Leerink | Outperform |
| 2019-03-20 | 開始されました | Needham | Buy |
| 2018-10-30 | 開始されました | Jefferies | Buy |
| 2018-09-21 | 開始されました | Cantor Fitzgerald | Overweight |
| 2017-08-31 | 開始されました | BTIG Research | Buy |
すべてを表示
Kalvista Pharmaceuticals Inc (KALV) 最新ニュース
Is KalVista Pharmaceuticals Inc. stock positioned well for digital economyGap Down & High Conviction Buy Zone Picks - newser.com
Real time scanner hits for KalVista Pharmaceuticals Inc. explainedQuarterly Earnings Summary & AI Powered Buy and Sell Recommendations - newser.com
Multi asset correlation models including KalVista Pharmaceuticals Inc.July 2025 Trends & Consistent Profit Trade Alerts - newser.com
What makes KalVista Pharmaceuticals Inc. stock attractive to growth funds2025 Earnings Surprises & Stock Portfolio Risk Control - newser.com
Will KalVista Pharmaceuticals Inc. (4XC1) stock keep high P E multiplesQuarterly Portfolio Review & Consistent Growth Equity Picks - newser.com
Citizens reiterates Market Outperform rating on Kalvista stock at $28 target - Investing.com Canada
How to manage a losing position in KalVista Pharmaceuticals Inc.Watch List & Fast Gaining Stock Strategy Reports - newser.com
What market sentiment indicators show for KalVista Pharmaceuticals Inc. (4XC1) stockQuarterly Investment Review & Low Drawdown Momentum Ideas - newser.com
Will KalVista Pharmaceuticals Inc. (4XC1) stock benefit from commodity supercycle2025 Institutional Moves & Real-Time Volume Analysis - newser.com
Citizens Touts KalVista Pharmaceuticals, Inc. (KALV) Growth Trajectory on EKTERLY Prospects - Insider Monkey
How KalVista Pharmaceuticals Inc. stock performs in high volatility marketsEarnings Recap Report & AI Based Buy and Sell Signals - newser.com
How hedge fund analytics apply to KalVista Pharmaceuticals Inc. stockJuly 2025 Review & Reliable Momentum Entry Alerts - newser.com
How strong is KalVista Pharmaceuticals Inc. (4XC1) stock earnings growthAnalyst Upgrade & Safe Entry Zone Tips - newser.com
Millennium Management LLC's Strategic Acquisition in KalVista Ph - GuruFocus
Will KalVista Pharmaceuticals Inc. stock attract more institutional investorsMarket Performance Report & Verified Short-Term Plans - newser.com
Why KalVista Pharmaceuticals Inc. (4XC1) stock is favored by hedge fundsMarket Performance Summary & AI Forecasted Entry and Exit Points - newser.com
Kalvista Pharmaceuticals stock rating maintained as Citizens notes Ekterly launch complexity - Investing.com Australia
Exit strategy if you’re trapped in KalVista Pharmaceuticals Inc.Earnings Recap Report & Daily Volume Surge Signals - newser.com
Is KalVista Pharmaceuticals Inc a good long term investmentTechnology Stock Trends & Low Cost Trading Tips - earlytimes.in
Hereditary Angioedema Market Forecast 2034Competitive - openPR.com
KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) Q3 2025 Earnings Call Transcript - Insider Monkey
Will a bounce in KalVista Pharmaceuticals Inc. offer an exitMarket Performance Recap & Risk Controlled Stock Alerts - newser.com
Five things for pharma marketers to know for Wednesday, November 12, 2025 - Medical Marketing and Media
KalVista Pharmaceuticals Reports Strong Q3 Results - TipRanks
Kalvista Pharmaceuticals Inc (KALV) 財務データ
収益
当期純利益
現金流量
EPS
1.38%
1.42%
大文字化:
|
ボリューム (24 時間):